http://neuropipeline.com/wp-admin/admin.php?page=wp-e-commerce/display-log.php This is the WP E-Commerce Product List RSS feed WP E-Commerce Plugin http://neuropipeline.com/?page_id=81&category=1&product_id=7 <p style="text-align: center;">Publication Date: July 12, 2009</p> <p style="text-align: center;">Number of Pages: 70 (35 for each report)</p> <p style="text-align: center;">Format: Instant Downloadable PDF</p> <p style="text-align: center;">Corporate User</p> Tue, 07 Sep 2010 14:18:37 -0500 http://neuropipeline.com/?page_id=81&category=1&product_id=7 299 http://neuropipeline.com/?page_id=81&category=1&product_id=6 <p style="text-align: center;">Publication Date: July 12, 2009</p> <p style="text-align: center;">Number of Pages: 35</p> <p style="text-align: center;">Format: Instant Downloadable PDF</p> <p style="text-align: center;">Corporate User</p> <p>&nbsp;</p> Tue, 07 Sep 2010 14:18:37 -0500 http://neuropipeline.com/?page_id=81&category=1&product_id=6 170 http://neuropipeline.com/?page_id=81&product_id=5 <p style="text-align: center;">Publication Date: July 12, 2009</p> <p style="text-align: center;">Number of Pages: 35</p> <p style="text-align: center;">Format: Instant Downloadable PDF</p> <p style="text-align: center;">Corporate User</p> <p>&nbsp;</p> Tue, 07 Sep 2010 14:18:37 -0500 http://neuropipeline.com/?page_id=81&product_id=5 170 http://neuropipeline.com/?page_id=81&category=1&product_id=4 <p style="text-align: center;">Publication Date: July 12, 2009</p> <p style="text-align: center;">Number of Pages: 70 (35 for each report)</p> <p style="text-align: center;">Format: Instant Downloadable PDF</p> <p style="text-align: center;">Single User</p> Tue, 07 Sep 2010 14:18:37 -0500 http://neuropipeline.com/?page_id=81&category=1&product_id=4 169 http://neuropipeline.com/?page_id=81&category=1&product_id=2 <p style="text-align: center;">Publication Date: July 12, 2009</p> <p style="text-align: center;">Number of Pages: 35</p> <p style="text-align: center;">Format: Instant Downloadable PDF</p> <p style="text-align: center;">Single User</p> <p>This report presents a critical analysis of the five oral compounds that are furthest along the regulatory pathway for the treatment of Multiple Sclerosis.&nbsp; These compounds have potential for FDA approval between 2010 and 2013.&nbsp; <br /><br />For each compound, the report includes an overview of early data, detailed review of the most recent Phase II or Phase III studies, analysis of efficacy, analysis of tolerability, analysis of safety and calendar.&nbsp; Comparisons to existing therapies and consideration of roadblocks to FDA approval are presented.&nbsp;</p> <p>Additional attitudes derived from conversations with more than 20 neurologists who manage a total of more than 8000 MS patients and from personal interactions with more than 350 MS patients are incorporated into the opinions.</p> Tue, 07 Sep 2010 14:18:37 -0500 http://neuropipeline.com/?page_id=81&category=1&product_id=2 89 http://neuropipeline.com/?page_id=81&product_id=1 <p style="text-align: center;">Publication Date: July 12, 2009</p> <p style="text-align: center;">Number of Pages: 35</p> <p style="text-align: center;">Format: Instant Downloadable PDF</p> <p style="text-align: center;">Single User</p> <p>This report analyzes injectible or infusible medications for multiple sclerosis that are in later stage development.&nbsp; These compounds have potential for FDA approval between 2011 and 2015.&nbsp;&nbsp; To be included in this report, a compound must have completed at least one Phase II study with results demonstrating some efficacy for MS.&nbsp; <br /><br />For each compound, the report includes an overview, mechanism of action, early data, detailed review of the most recent Phase II studies, analysis of efficacy, analysis of tolerability, analysis of safety and calendar.&nbsp; Comparisons to existing therapies and consideration of roadblocks to FDA approval are presented.&nbsp; Additional, attitudes derived from conversations with more than 20 neurologists who manage a total of more than 8000 MS patients and from personal interactions with more than 350 MS patients are incorporated into the opinions.</p> Tue, 07 Sep 2010 14:18:37 -0500 http://neuropipeline.com/?page_id=81&product_id=1 89